Skip to main content
. 2017 Jan 1;28(1):99–111. doi: 10.1089/hum.2016.117

Table 4.

Serious adverse events

Serious adverse events Cohort 1 + 2, N = 6 (%) Cohort 3 + 4, N = 15 (%)
Intraductal proliferative breast lesion 1 (16.7) 0 (0)
Macular hole 0 (0) 1 (6.7)
Osteoarthritis 1 (16.7) 0 (0)
Pneumonia 1 (16.7) 0 (0)
Pneumothorax 0 (0) 1 (6.7)
Urinary tract infection 0 (0) 1 (6.7)